uniQure N.V. (QURE) |
|
17.3 -0.29 (-1.65%)
|
09-24 16:22 |
|
Open: |
17.43 |
Pre. Close: |
17.59 |
|
High:
|
17.46 |
Low:
|
16.99 |
|
Volume:
|
595,819 |
Market Cap:
|
808(M) |
|
|
|
|
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
17.57 - 17.74 |
17.74 - 17.84 |
|
Low:
|
16.63 - 16.85 |
16.85 - 16.99 |
|
Close:
|
17.05 - 17.41 |
17.41 - 17.63 |
|
Technical analysis |
as of: 2022-09-23 4:27:00 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 23.26  One year: 25.38 |
| Support: |
Support1: 16.98 Support2: 14.13 |
| Resistance: |
Resistance1: 19.91 Resistance2: 21.72 |
| Pivot: |
19.64 |
| Moving Average: |
MA(5): 18.16 MA(20): 19.68
MA(100): 18.75  MA(250): 20.83 |
| MACD: |
MACD(12,26): -0.7 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 4.7 %D(3): 5.5 |
| RSI: |
RSI(14): 34.3 |
| 52-week: |
High: 36.54 Low: 12.52 |
| Average Vol(K): |
3-Month: 668 (K) 10-Days: 754 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ QURE ] has closed above bottom band by 1.4%. Bollinger Bands are 5.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 23 Sep 2022
Alexander Edward Kuta III Sells 2306 Shares of uniQure (NASDAQ:QURE) Stock - MarketBeat
Fri, 23 Sep 2022
The challenges of verifying AI for healthcare - ComputerWeekly.com
Thu, 22 Sep 2022
Health Care Partners Collaborate On Lung Cancer Diagnosis With AI Tech - CodeBlue
Fri, 16 Sep 2022
Industry news in brief - Digital Health
Tue, 13 Sep 2022
Qure for Sure: The definitive guide to implementing AI in your NHS Trust - Digital Health
Fri, 09 Sep 2022
Bleepa, an innovative digital solution that allows doctors to collaborate with peers to achieve better patient outcomes - The Hindu
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
47 (M) |
| Shares Float |
32 (M) |
|
% Held by Insiders
|
7 (%) |
|
% Held by Institutions
|
97.2 (%) |
|
Shares Short
|
3,500 (K) |
|
Shares Short P.Month
|
4,140 (K) |
Stock Financials |
|
EPS
|
7.59 |
|
EPS Est Next Qtl
|
-0.7 |
|
EPS Est This Year
|
-2.98 |
|
EPS Est Next Year
|
-2.66 |
|
Book Value (p.s.)
|
10.42 |
|
Profit Margin (%)
|
-184.1 |
|
Operating Margin (%)
|
-235.6 |
|
Return on Assets (ttm)
|
-12.3 |
|
Return on Equity (ttm)
|
-20.4 |
|
Qtrly Rev. Growth
|
-100 |
|
Gross Profit (p.s.)
|
7.75 |
|
Sales Per Share
|
1.32 |
|
EBITDA (p.s.)
|
-2.96 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-129 (M) |
|
Levered Free Cash Flow
|
-86 (M) |
Stock Valuations |
|
PE Ratio
|
2.27 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.66 |
|
Price to Sales
|
13.04 |
|
Price to Cash Flow
|
-6.29 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
